首页> 美国卫生研究院文献>Journal of Enzyme Inhibition and Medicinal Chemistry >3D QSAR studies pharmacophore modeling and virtual screening of diarylpyrazole–benzenesulfonamide derivatives as a template to obtain new inhibitors using human carbonic anhydrase II as a model protein
【2h】

3D QSAR studies pharmacophore modeling and virtual screening of diarylpyrazole–benzenesulfonamide derivatives as a template to obtain new inhibitors using human carbonic anhydrase II as a model protein

机译:3D QSAR研究药效团建模和以人碳酸酐酶II为模型蛋白的二芳基吡唑-苯磺酰胺衍生物作为模板的虚拟筛选以获得新的抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 3D-QSAR modeling was performed on a series of diarylpyrazole-benzenesulfonamide derivatives acting as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). The compounds were collected from two datasets with the same scaffold, and utilized as a template for a new pharmacophore model to screen the ZINC database of commercially available derivatives. The datasets were divided into training, test, and validation sets. As the first step, comparative molecular field analysis (CoMFA), CoMFA region focusing and comparative molecular similarity indices analysis (CoMSIA) in parallel with docking studies were applied to a set of 41 human (h) CA II inhibitors. The validity and the prediction capacity of the resulting models were evaluated by leave-one-out (LOO) cross-validation approach. The reliability of the model for the prediction of possibly new CA inhibitors was also tested.
机译:对一系列用作金属酶碳酸酐酶抑制剂的二芳基吡唑-苯磺酰胺衍生物进行了3D-QSAR建模(CA,EC 4.2.1.1)。从具有相同支架的两个数据集中收集化合物,并将其用作新药效团模型的模板,以筛选市售衍生物的ZINC数据库。数据集分为训练集,测试集和验证集。作为第一步,与对接研究同时进行的比较分子场分析(CoMFA),CoMFA区域聚焦和比较分子相似性指标分析(CoMSIA)被应用于一组41种人(h)CA II抑制剂。通过留一法(LOO)交叉验证方法评估了所得模型的有效性和预测能力。还测试了用于预测可能的新型CA抑制剂的模型的可靠性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号